Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

By T. Vesikari, D. Matson, P. Dennehy, P. van Damme, M. Santosham, Zoe M. Rodriguez, M. Dallas, J. Heyse, Michelle G. Goveia, S. Black and 18 more. New England Journal of Medicine, 2006

1,801 citations recorded by the source corpus.

Subfields: Infectious Diseases, Small Animals

View Paper: https://www.semanticscholar.org/paper/0b2f9820d64886826e5c2cea5188ab176a814d8e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Cortese
2. Umesh D. Parashar

Citations in the corpus

• Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013 (2016, background): “cines (RotaTeq, Merck & Co and Rotarix, GSK Biologicals) have been licensed in >100 countries worldwide [1, 2].”
• Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). (2009, background): “The efficacy of the final formulation of RV5 has been evalu­ ated in two phase III trials among healthy infants (92,93).”